Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: Hardware that is configured to gather data on a process line. These configurations may include devices that can connect to existing process control networks, like 4-20 mA control loops. These devices may include rechargeable power sources, for example, a supercapacitor. This power source can power a sensor or like hardware that resides in proximity to a control valve or other device on the process line. The sensor may require a power level for a short time that significantly exceeds one available from 4-20 mA current loop network. As an added benefit, the circuitry may find use to allow the power source to store power, or re-charge, at periodic intervals to ensure that the sensor can gather data regularly during the lifetime of the control valve.

Abstract: The present disclosure provides a mechanism for data transfer for a robot using pre-existing network standards (e.g., USB-C, Thunderbolt, CAN-bus, or Ethernet) and for power delivery, both being implemented through direct contact pins on a robot and the corresponding contact pads on a docking station. The robot can be a legged or wheeled ground vehicle, an aerial vehicle such as a drone, an underwater robot, or any other suitable robots. The docking station may include a computing device, to which the robot can transfer data. The contact pins and pads can be arranged to have a rotational symmetry.

Abstract: Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used in cases where oral administration of drug is not possible due to underlying conditions or concern around inadequate oral absorption.

Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.

Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Abstract: A concentrated poly(ethylene glycol) solution that has good stability for extended storage is provided for use as a laxative. The concentrated solution comprises water, sodium benzoate, poly(ethylene glycol), and enough acid to yield a solution having a pH at 25° C. in the range 3.0-5.0. It is prepared and packaged to minimize the accumulation of degradation products.

Abstract: The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.

Abstract: The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.

Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.

Abstract: The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.

Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.

Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.